Published:
Catalent Pharma Solutions Enters a Strategic Alliance with Endotis Pharma
SOMERSET, N.J. - (BUSINESS WIRE) - Catalent Pharma Solutions, the leading provider of advanced oral drug
delivery technologies to the pharmaceutical industry, has entered into a
strategic alliance with Endotis Pharma for the development of oral
formulations of synthetic oligosaccharides.
Using Catalent's drug delivery technologies, the two companies will
collaborate exclusively to develop certain oral formulations of
small-glycol drugs. Oral formulations of synthetic oligosaccharides will
allow full exploitation of the therapeutic potential of small-glycol
drugs, which to date are administered only intravenously or
subcutaneously.
Catalent and Endotis are initially focusing on the preclinical
development of Endotis' EP37151 compound. EP37151 is a first-in-class
oral synthetic oligosaccharide anticoagulant which, as an indirect
factor Xa inhibitor, acts via antithrombin activation. The companies
expect to initiate a Phase I clinical trial program during the second
quarter of 2010, and hope to have more oral anticoagulants enter
development within the next year.
"This collaboration with Endotis, based upon a unique combination of
complementary expertise, has been providing exciting results, proving
that the various technical hurdles associated with the oral delivery of
small-glycol drugs can be overcome," said Tom Stuart, Group President of
Catalent's Oral Technologies segment.
About Catalent
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a
leading provider of advanced dose form and packaging technologies, and
development, manufacturing and packaging services for pharmaceutical,
biotechnology and consumer healthcare companies in nearly 100 countries.
Catalent applies its local market expertise and technical creativity to
advance treatments, change markets and enhance patient outcomes.
Catalent employs approximately 9,500 at 30 facilities worldwide and in
fiscal 2009 generated more than $1.6 billion in annual revenue. For more
information, visit www.catalent.com.
Catalent Pharma Solutions
Patricia A. McGee, 732-537-6407
patricia.mcgee@catalent.com
Copyright © 2009, Business Wire, Inc., All rights reserved.
Copyright © 2009, NewsBlaze,
Daily NewsTags: Business wire, Healthcare, new jersey, Health, Pharmaceuticals
Search News
Daily News
